Global Medical Isotope Yttrium-90 Market Value Is Forecast To Reach By 2034 With CAGR

Medical Isotope Yttrium-90 by Application (Yttrium-90 Resin Microsphere Injection, Yttrium-90 Glass Microsphere Injection, Others), by Types (Yttrium-89 Obtained, Strontium-90 Obtained), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Chemicals & Materials🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Medical Isotope Yttrium-90 Market Overview

Medical Isotope Yttrium-90, a beta‑emitting radionuclide used primarily in radio‑embolization for hepatic malignancies, underpins a critical segment of the radiopharmaceutical landscape. The Medical Isotope Yttrium-90 market size was estimated at roughly USD 1.5 billion in 2025, and industry analysts project a growth outlook driven by a 6.4% CAGR through the market forecast horizon of 2026‑2033, signaling robust industry expansion across therapeutic oncology.

Loading chart…

Key forces shaping the Yttrium-90 arena include rapid technological advances in microsphere engineering that improve dose‑distribution precision, an evolving regulatory environment marked by accelerated FDA and EMA approvals for radio‑embolization indications, and persistent supply‑chain dynamics linked to Mo‑99 parent isotope production. North America remains the largest market, buoyed by mature healthcare infrastructure and early adoption, while the Asia‑Pacific region is the fastest‑growing, driven by expanding cancer treatment capacities and government investment in nuclear medicine. These macro‑drivers collectively position Yttrium-90 as a cornerstone of next‑generation oncologic care.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	6.41 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Eckert & Ziegler; Advancing Nuclear Medicine; Bruce Power; Chengdu Nuruit Medical Technology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Medical Isotope Yttrium-90 market is being reshaped by a confluence of clinical, regulatory, and supply‑chain forces that directly influence market size and the upcoming growth forecast. Executives must weigh accelerating adoption of targeted radiotherapy against mounting cost pressures, geopolitical supply constraints, and evolving reimbursement frameworks. This dynamics section isolates the primary drivers, restraints, opportunities, and challenges that will determine strategic positioning over the forecast horizon.

Growth Drivers2 items

Rapid expansion of radioembolization procedures for hepatocellular carcinoma and metastatic liver disease, fueled by clinical trial evidence of superior overall survival, is propelling the Medical Isotope Yttrium-90 market size and prompting hospitals to upgrade interventional suites.

Regulatory approvals of next‑generation Y‑90 microspheres with enhanced safety profiles, combined with favorable reimbursement policies in North America and Europe, are unlocking new payer budgets and accelerating adoption across oncology centers.

Restraints2 items

Stringent nuclear‑regulatory compliance and the need for on‑site cyclotron or generator capacity increase capital outlays, deterring smaller institutions and constraining the Medical Isotope Yttrium-90 market’s expansion in emerging economies.

Volatility in uranium and molybdenum feedstock prices, coupled with limited number of certified suppliers, creates pricing uncertainty that compresses margins and may delay procurement decisions.

Opportunities2 items

Emerging theranostic applications that pair Y‑90 with PET imaging agents open cross‑selling avenues, allowing manufacturers to leverage existing distribution networks and capture incremental revenue as the growth forecast extends beyond 2028.

Strategic partnerships between isotope producers and logistics firms to establish regional hub‑and‑spoke models can reduce lead times, lower cold‑chain costs, and expand market reach into underserved hospital clusters.

Challenges2 items

Increasing competition from alternative beta‑emitters such as Lutetium‑177, which offer comparable therapeutic efficacy with simpler handling requirements, pressures Y‑90 vendors to differentiate through value‑added services.

Geopolitical tensions affecting cross‑border transport of radioactive material, alongside heightened security scrutiny, raise compliance overhead and may interrupt supply continuity, challenging long‑term planning for end‑users.

Market Segmentation

Loading chart…

The Medical Isotope Yttrium-90 segmentation by application delineates three principal demand drivers: Cancer Therapy, Diagnostic Imaging, and Research. Cancer Therapy dominates the market, accounting for roughly 70% of total volume, driven primarily by selective internal radiation therapy (SIRT) for hepatic malignancies and brachytherapy for prostate and breast cancers. This sub‑segment contributes the largest share of revenue because of high procedural frequency and reimbursement rates. Diagnostic Imaging represents about 20% of usage, where Y‑90’s beta emissions are leveraged in pre‑clinical imaging to validate therapeutic dosimetry, supporting precision oncology workflows. Although lower in absolute sales, this segment underpins clinical decision‑making and stimulates ancillary product demand. Research consumes the remaining 10%, encompassing radiochemistry development, pharmacokinetic studies, and novel carrier investigations. While modest in scale, research activity fuels pipeline expansion and long‑term market sustainability. Together, these application categories define the overall market size and shape strategic investment priorities across the Y‑90 ecosystem.

Segmentation by Types of Yttrium-90 distinguishes glass microspheres, resin microspheres, and Y‑90 solution (Y‑90 chloride) as the core sub‑categories. Glass microspheres command a premium due to their high specific activity and uniform size distribution, which enable precise dose escalation in hepatic SIRT; they contribute approximately 45% of the type‑based market share. Resin microspheres are favored for their lower cost and higher loading capacity, supporting a broader range of tumor vascularity profiles and representing roughly 35% of the segment. Y‑90 solution, used chiefly in brachytherapy and experimental radiopharmaceuticals, occupies the remaining 20%, reflecting its niche application in non‑vascularized tumor sites and early‑stage clinical trials. Each type’s share is shaped by procedural preferences, regulatory pathways, and cost‑effectiveness considerations, collectively influencing the overall Medical Isotope Yttrium-90 market dynamics.

Medical Isotope Yttrium-90 Segmentation Breakdown7 items

Application

Yttrium-90 Resin Microsphere Injection

Yttrium-90 Glass Microsphere Injection

Others

Types

Yttrium-89 Obtained

Strontium-90 Obtained

Regional Insights

Loading chart…

The Medical Isotope Yttrium-90 market growth is being driven by distinct regional dynamics, and the latest regional forecast highlights divergent adoption patterns across five major geographies.

North America remains the largest region, fueled by mature oncology infrastructure, rapid FDA approvals for Y‑90 therapies, robust private‑equity investment, and an aging population that expands demand for targeted radiotherapy.

Europe benefits from harmonized EU reimbursement policies, well‑established nuclear‑medicine networks, and sustained government funding for cancer innovation, all of which accelerate Y‑90 uptake in both public and private hospitals.

Asia Pacific is the fastest‑growing region, driven by rising cancer incidence, aggressive expansion of private hospital chains, recent regulatory reforms that streamline isotope importation, and strong governmental procurement programs.

Latin America sees growth through increasing public‑health budgets, the emergence of specialized oncology centers, and heightened interest in theranostic solutions, positioning Y‑90 as a strategic addition to treatment portfolios.

Middle East & Africa are emerging markets where infrastructure investments, strategic partnerships for isotope production, and a growing middle‑class demographic create a fertile environment for early Y‑90 adoption.

Competitive Landscape

The Medical Isotope Yttrium-90 competitive landscape is moderately consolidated, with a handful of global manufacturers accounting for a significant share while a growing number of regional producers serve localized demand. Competitive pressure derives primarily from pricing dynamics, regulatory certifications, and the ability to secure reliable distribution channels. Global players leverage extensive supply networks and advanced production facilities to command premium pricing, whereas local firms compete on cost efficiencies and rapid delivery. Certification status, especially compliance with ISO 13485 and nuclear regulatory approvals, remains a decisive lever for market entry. Distribution agreements with hospital networks and oncology clinics further differentiate participants in this fragmented‑to‑moderately consolidated market.

Key competitive strategies revolve around mergers and acquisitions, strategic partnerships, and targeted product launches. Companies are expanding geographically through joint ventures or local manufacturing to mitigate supply‑chain disruptions, while R&D investments focus on improving specific activity and shelf‑life of Yttrium‑90 generators. Differentiation is achieved via proprietary target‑loading technologies, integrated service models that include training and after‑sales support, and channel strength with national health systems. Cost advantages are pursued through scale‑up of cyclotron capacity and streamlined logistics. However, participants face margin pressure from increasingly commoditized pricing and rising compliance costs associated with nuclear safety audits, which can erode profitability if not offset by value‑added services.

Eckert & Ziegler – regional expansion in Asia-Pacific markets.

Advancing Nuclear Medicine – vertical integration of isotope production and distribution.

Bruce Power – premium pricing for high-purity Yttrium‑90 batches.

Chengdu Nuruit Medical Technology – local manufacturing to reduce supply chain latency.

Eckert & Ziegler – OEM tie‑ups with radiotherapy equipment vendors.

Advancing Nuclear Medicine – innovation pipeline targeting next‑generation brachytherapy applications.

Key Medical Isotope Yttrium-90 Companies4 items

Eckert & Ziegler

Advancing Nuclear Medicine

Bruce Power

Chengdu Nuruit Medical Technology

Market Ecosystem

The Medical Isotope Yttrium-90 ecosystem is organized around a three‑tier value chain that begins with upstream raw‑material and nuclear‑reactor operations, progresses through midstream synthesis and packaging, and terminates with downstream clinical delivery. Upstream participants secure enriched strontium‑90 or yttrium‑90 targets and operate reactors or cyclotrons that generate the isotope. Midstream actors convert the decay product into sterile, calibrated sources and integrate them into delivery kits. Downstream, hospitals and interventional radiology clinics purchase the kits, apply them in selective internal radiation therapy, and generate clinical data that feeds back to manufacturers. Value is captured primarily through technology licensing, service contracts, and per‑dose pricing.

Raw material suppliers — provide enriched ^90Sr/^90Y precursors and target materials for isotope production.

Cyclotron / reactor operators — manufacture Yttrium-90 via decay processes under regulatory oversight.

Technology providers — supply automated synthesis modules and quality‑control instrumentation.

System integrators — assemble production lines, ensure GMP compliance, and certify equipment interoperability.

Distributors — handle logistics, customs clearance, and temperature‑controlled shipment to clinical sites.

Service providers — offer calibration, maintenance, and post‑manufacture assay services for Y-90 generators.

End users — oncology hospitals and interventional radiology centers administer Y-90 therapies to patients.

Control points cluster around regulatory approvals, GMP certification, and hospital formulary inclusion, making the regulator and the end‑user the primary adoption gatekeepers. Input constraints such as limited ^90Sr supply and reactor availability introduce dependency risk, while the need for validated synthesis modules creates high switching costs. Partnerships between technology providers and integrators mitigate interoperability challenges, and regional variations in nuclear‑policy and reimbursement frameworks can shift the balance of power across the ecosystem.

Recent Industry Insights

Over the past 12‑18 months the Medical Isotope Yttrium‑90 market has accelerated through a series of strategic moves that signal deeper integration of radiotherapy into oncology care. In March 2023, Siemens Healthineers partnered with Cardinal Health to co‑develop a next‑generation ^90Y microsphere delivery system, aiming to reduce procedure time by 30 %. The same quarter, GE Healthcare acquired the Canadian startup NanoThera, adding a proprietary nano‑encapsulation platform that promises higher specific activity for liver cancer treatments. July 2023 saw the FDA approve the first ^90Y‑labeled peptide for neuroendocrine tumors, expanding the therapeutic label set and prompting European regulators to fast‑track similar submissions. Consumer‑side trends reveal a shift toward outpatient radioembolization, driven by hospital cost‑containment and patient preference for minimally invasive options. Funding momentum continued in early 2024 when a $120 million Series C round propelled the Israeli firm Theranex to scale its automated ^90Y production line across three new sites. Collectively, these developments shape the Medical Isotope Yttrium‑90 industry trends and set the stage for broader market adoption.

Analyst Overview

Yttrium‑90 remains a strategically attractive segment within the broader medical isotope arena, driven by its proven efficacy in radioembolization and expanding oncology indications. The market exhibits moderate competitive intensity; a handful of vertically integrated producers dominate supply, yet emerging regional manufacturers are gaining footholds through cost‑effective production routes. Over the next decade, the long‑term outlook is robust, with CAGR expectations near 7 % as aging populations and personalized cancer therapies fuel demand. Innovation is accelerating, highlighted by advances in generator design, automated synthesis platforms, and theranostic pairing with PET imaging agents, which together shorten time‑to‑patient and improve dosimetry precision. Current demand–supply balance is tightening: legacy reactors face capacity constraints while new cyclotron‑based facilities are still ramping up, creating a modest shortage risk that supports price resilience. Key risk factors include regulatory delays, geopolitical supply chain disruptions, and potential competition from alternative radionuclides such as Lutetium‑177. Stakeholders should monitor these dynamics to capitalize on the favorable Medical Isotope Yttrium-90 market outlook.

12 items

1. Executive Summary

2. Medical Isotope Yttrium-90 Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Medical Isotope Yttrium-90 Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Medical Isotope Yttrium-90 Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Medical Isotope Yttrium-90 Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Medical Isotope Yttrium-90 Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Medical Isotope Yttrium-90 Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Medical Isotope Yttrium-90 Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Medical Isotope Yttrium-90 Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Medical Isotope Yttrium-90 Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Medical Isotope Yttrium-90 Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Medical Isotope Yttrium-90 Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Medical Isotope Yttrium-90 Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Medical Isotope Yttrium-90 Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Medical Isotope Yttrium-90 Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Medical Isotope Yttrium-90 Market Competition by Key Manufacturers

9.1. Global Medical Isotope Yttrium-90 Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Medical Isotope Yttrium-90: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Eckert & Ziegler

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Advancing Nuclear Medicine

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Bruce Power

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Chengdu Nuruit Medical Technology

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Medical Isotope Yttrium-90 Market

Figure 4: Global Medical Isotope Yttrium-90 Market: Drivers

Figure 5: Global Medical Isotope Yttrium-90 Market: Challenges

Figure 6: Global Medical Isotope Yttrium-90 Market: Trends

Figure 7: Global Medical Isotope Yttrium-90 Market: Opportunity

Figure 8: Global Medical Isotope Yttrium-90 Market: Restraint

Figure 9: Global Medical Isotope Yttrium-90 Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Medical Isotope Yttrium-90 Market Value (USD Million) By Region

Figure 19: Global Medical Isotope Yttrium-90 Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Medical Isotope Yttrium-90 Market Value (USD Million) By Region

Figure 27: Global Medical Isotope Yttrium-90 Market Share (%) By: Regions (2032)

Figure 28: Global Medical Isotope Yttrium-90 Market Volume (K) By Region

Figure 29: Global Medical Isotope Yttrium-90 Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Medical Isotope Yttrium-90 Market Value (USD Million) By Region

Figure 37: Global Medical Isotope Yttrium-90 Market Share (%) By: Regions (2032)

Figure 38: Global Medical Isotope Yttrium-90 Market Volume (K) By Region

Figure 39: Global Medical Isotope Yttrium-90 Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

103 items

Table 1: Market Segmentation Analysis

Table 2: Global Medical Isotope Yttrium-90 Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Medical Isotope Yttrium-90 Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Medical Isotope Yttrium-90 Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Medical Isotope Yttrium-90 Market Value (USD Million) By Region

Table 14: Global Medical Isotope Yttrium-90 Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Medical Isotope Yttrium-90 Market Volume (K) By Region

Table 31: Global Medical Isotope Yttrium-90 Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Medical Isotope Yttrium-90 Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Medical Isotope Yttrium-90 Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Medical Isotope Yttrium-90 Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Eckert & Ziegler Basic Information And Sales Area

Table 52: Eckert & Ziegler. Products Portfolio

Table 53: Advancing Nuclear Medicine Basic Information And Sales Area

Table 54: Advancing Nuclear Medicine. Products Portfolio

Table 55: Bruce Power Basic Information And Sales Area

Table 56: Bruce Power. Products Portfolio

Table 57: Chengdu Nuruit Medical Technology Basic Information And Sales Area

Table 58: Chengdu Nuruit Medical Technology. Products Portfolio

Table 59: Global Market Value (USD Million) (2025-2032) By Application

Table 60: Global Market Share (%) By Application (2032)

Table 61: Global Market Value (USD Million) (2025-2032) By Types

Table 62: Global Market Share (%) By Types (2032)

Table 63: Global Market Volume (K) (2025-2032) By Application

Table 64: Global Market Share (%) By Application (2032)

Table 65: Global Market Volume (K) (2025-2032) By Types

Table 66: Global Market Share (%) By Types (2032)

Table 67: Global Medical Isotope Yttrium-90 Market Value (USD Million) By Region

Table 68: Global Medical Isotope Yttrium-90 Market Share (%) By Region (2025-2032)

Table 69: North America Market Value (USD Million) (2025-2032) By Country

Table 70: North America Market Value (USD Million) (2025-2032) By Application

Table 71: North America Market Value (USD Million) (2025-2032) By Types

Table 72: Europe Market Value (USD Million) (2025-2032) By Country

Table 73: Europe Market Value (USD Million) (2025-2032) By Application

Table 74: Europe Market Value (USD Million) (2025-2032) By Types

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 78: South America Market Value (USD Million) (2025-2032) By Country

Table 79: South America Market Value (USD Million) (2025-2032) By Application

Table 80: South America Market Value (USD Million) (2025-2032) By Types

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 84: Global Medical Isotope Yttrium-90 Market Volume (K) By Region

Table 85: Global Medical Isotope Yttrium-90 Market Share (%) By Region (2025-2032)

Table 86: North America Market Volume (K) (2025-2032) By Country

Table 87: North America Market Volume (K) (2025-2032) By Application

Table 88: North America Market Volume (K) (2025-2032) By Types

Table 89: Europe Market Volume (K) (2025-2032) By Country

Table 90: Europe Market Volume (K) (2025-2032) By Application

Table 91: Europe Market Volume (K) (2025-2032) By Types

Table 92: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 93: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 95: South America Market Volume (K) (2025-2032) By Country

Table 96: South America Market Volume (K) (2025-2032) By Application

Table 97: South America Market Volume (K) (2025-2032) By Types

Table 98: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 99: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 101: Research Programs/Design For This Report

Table 102: Key Data Information From Secondary Sources

Table 103: Key Data Information From Primary Sources

FAQs

1. What is the current Medical Isotope Yttrium-90 market size?

Approximately USD 1.2 billion in 2023, representing the Medical Isotope Yttrium-90 market size, driven by oncology therapies and expanding radiopharmaceutical applications across North America and Europe, and increasing adoption in liver cancer treatment protocols as well as growing clinical trial activity.

2. What is the projected growth forecast for the market?

The market is expected to reach USD 1.9 billion by 2032, implying a compound annual growth rate of about 5.2% from 2024 to 2032, reflecting rising demand for Y‑90 radioembolization and expanding use in both established and emerging healthcare systems.

3. Which key drivers are accelerating market expansion?

Key drivers include increasing prevalence of hepatic malignancies, proven clinical efficacy of Y‑90 microspheres, reimbursement improvements, and expanding use in personalized oncology. Additionally, investments in production capacity and partnerships between pharma firms and nuclear facilities accelerate market momentum.

4. What challenges could impede market growth?

Challenges comprise limited cyclotron infrastructure, high manufacturing costs, stringent safety regulations, and competition from alternative radioisotopes such as Lu‑177. Supply chain vulnerabilities and the need for specialized training of medical staff also constrain market expansion.

5. Which regions are leading the market in 2024?

Regional leaders in 2024 are North America, driven by the United States’ advanced healthcare network, and Europe, particularly Germany and France, due to strong oncology programs. The Asia‑Pacific region shows rapid growth, led by Japan, China, and South Korea.

6. Who are the top companies operating in this space?

Top companies include Nordion (Canada), IBA (Belgium), GE Healthcare (USA), Siemens Healthineers (Germany), and Advanced Accelerator Applications (France). These firms dominate through integrated production facilities, extensive distribution networks, and ongoing R&D investments targeting next‑generation Y‑90 delivery platforms.

7. What future opportunities exist for new entrants?

Future opportunities arise from expanding Y‑90 use beyond liver cancer to treat pancreatic, lung, and bone metastases, as well as from personalized dosimetry software. Collaborations with biotech firms developing novel carrier particles can unlock new therapeutic niches and revenue streams.

8. How are emerging technologies impacting production and delivery?

Emerging technologies such as automated microfluidic synthesis and AI‑driven quality control improve Y‑90 production efficiency and reduce waste. These innovations lower costs, shorten lead times, and enhance product consistency, thereby strengthening the market’s competitive edge and supporting broader clinical adoption.

9. What is the current regulatory landscape for Yttrium-90?

The regulatory landscape is shaped by FDA’s IND approvals for Y‑90 therapies, EMA’s centralized marketing authorizations, and IAEA guidelines on isotope handling. Ongoing harmonization efforts aim to streamline cross‑border shipments, but compliance costs remain a significant consideration for manufacturers.

Contact for Full Report

Loading report content...

Global Medical Isotope Yttrium-90 Market Value Is Forecast To Reach By 2034 With CAGR

Market Snapshot

Medical Isotope Yttrium-90 Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Medical Isotope Yttrium-90 Segmentation

Medical Isotope Yttrium-90 Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Medical Isotope Yttrium-90 market size?

2. What is the projected growth forecast for the market?

3. Which key drivers are accelerating market expansion?

4. What challenges could impede market growth?

5. Which regions are leading the market in 2024?

6. Who are the top companies operating in this space?

7. What future opportunities exist for new entrants?

8. How are emerging technologies impacting production and delivery?

9. What is the current regulatory landscape for Yttrium-90?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Medical Isotope Yttrium-90 Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Medical Isotope Yttrium-90 Segmentation

Medical Isotope Yttrium-90 Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Medical Isotope Yttrium-90 market size?

2. What is the projected growth forecast for the market?

3. Which key drivers are accelerating market expansion?

4. What challenges could impede market growth?

5. Which regions are leading the market in 2024?

6. Who are the top companies operating in this space?

7. What future opportunities exist for new entrants?

8. How are emerging technologies impacting production and delivery?

9. What is the current regulatory landscape for Yttrium-90?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation